THC/CBD for Severe Dementia Behavioral Symptoms: A Two-Year Safety Pilot | Research

The takeaway

In 19 elderly patients with severe dementia, two years of THC/CBD treatment appeared safe and was associated with reduced agitation and behavioral symptoms — but without a control group, the results are suggestive, not conclusive.

Read this if you care for someone with dementia and are curious whether medical cannabis might help with agitation or behavioral symptoms — this is an early safety signal, not a treatment recommendation.

What the researchers found

Managing behavioral symptoms in severe dementia — agitation, aggression, wandering, sleep disruption — is one of the hardest challenges in elder care. Antipsychotic medications are commonly used but carry serious risks including increased mortality in this population. This pilot study asked whether medical cannabis could offer a safer alternative.

Nineteen patients (average age 81, mostly women) with severe dementia in a Swiss long-term care facility received THC/CBD treatment as an add-on to their existing medications over two years. These were heavily medicated patients, averaging 12.4 mg of THC equivalent per day on top of their other prescriptions.

The key finding is safety: over two years of continuous use, no serious adverse events were attributed to the cannabis treatment. This is significant because these patients were elderly, frail, on multiple medications, and had the kind of comorbidities that make drug interactions a real concern. Blood tests monitoring cannabinoid levels and liver enzymes showed that the treatment was pharmacokinetically manageable even in this vulnerable population.

Clinically, the researchers observed improvements in agitation, behavioral disturbances, and rigidity scores, though without a control group, it's impossible to know how much of this improvement was due to the cannabis treatment versus natural fluctuation or placebo effects.

Why it matters

Behavioral symptoms in dementia affect up to 90% of patients and are a primary reason for institutionalization and caregiver burnout. Current pharmacological options (mainly antipsychotics) carry FDA black box warnings for increased mortality in elderly dementia patients. If cannabinoids can safely reduce behavioral symptoms, they could offer a better risk-benefit profile — but this needs to be proven in controlled trials. This pilot provides the safety data needed to justify those larger studies.

The numbers in context

19 patients (17 women, 2 men), average age 81.4 years. Average THC dose: 12.4 mg/day. Follow-up: 2 years. No serious adverse events attributed to cannabis treatment. The study measured plasma cannabinoid levels and CYP450 enzyme activity to monitor for drug interactions in this polymedicated population.

How the study worked

Prospective observational study following 19 patients with severe dementia in a Swiss long-term care home. Patients received physician-prescribed THC/CBD treatment as an add-on to existing medications. Data collected over two years included cannabis dosages, safety parameters, neuropsychiatric inventory scores, agitation ratings, rigidity assessments, and pharmacokinetic measurements (plasma cannabinoid levels and enzyme activity).

Who was studied

N=19 patients aged 81.4 years, 17 women and 2 men, living in a long-term care home in Switzerland

What this study cannot tell us

No control group — the biggest limitation. Without randomization and placebo comparison, improvements could reflect natural symptom fluctuation, placebo effects, or increased caregiver attention. Very small sample (19 patients) from a single facility. The patient population was predominantly female (17/19), limiting generalizability. Two-year retention data may reflect survivorship bias in this elderly, severely ill population.

How to read the evidence

This is a small observational pilot study with no control group. It provides useful safety data for a vulnerable population but cannot establish whether the treatment actually caused the observed improvements.

When this study was published

Published in 2022. Larger controlled trials may be underway based on this pilot's safety findings.

The bigger picture

This study sits alongside RTHC-00080 (cannabinoids for Parkinson's and dementia in older adults), building the case that cannabinoids may have a role in managing neurodegenerative disease symptoms in elderly patients. The drug interaction monitoring in this study also connects to the broader pharmacokinetic work in RTHC-00091 (CYP450 cannabinoid-drug interactions) — critical for a population taking multiple medications.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

Would a randomized controlled trial confirm the behavioral improvements seen in this pilot? What's the optimal THC:CBD ratio for managing dementia behavioral symptoms? Can cannabinoids reduce or replace antipsychotic use in dementia, and would that improve mortality outcomes?

Read the original research

Cannabinoids for behavioral symptoms in severe dementia: Safety and feasibility in a long-term pilot observational study in nineteen patients.

Frontiers in aging neuroscience, 14, 957665

Frontiers in Aging Neuroscience is a reputable journal focusing on research related to aging and neuroscience.

View on PubMed ↗Publisher’s paper ↗

Citation

Pautex, Sophie; Bianchi, Federica; Daali, Youssef; Augsburger, Marc; de Saussure, Christian; Wampfler, James; Curtin, François; Desmeules, Jules; Broers, Barbara. (2022). Cannabinoids for behavioral symptoms in severe dementia: Safety and feasibility in a long-term pilot observational study in nineteen patients.. Frontiers in aging neuroscience, 14, 957665. https://doi.org/10.3389/fnagi.2022.957665